catalym
Posted by catalym
March 1, 2022
March 1, 2022

CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase 1 Completion

CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase...

Read More
catalym
Posted by catalym
January 26, 2022
January 26, 2022

BIO EUROPE SPRING 2022

March 28-31, 2022

Read More
catalym
Posted by catalym
January 26, 2022
January 26, 2022

AACR 2022

April 8-13, 2022

Read More
catalym
Posted by catalym
January 26, 2022
January 26, 2022

ASCO 2022

June 3-7, 2022

Read More
catalym
Posted by catalym
January 26, 2022
January 26, 2022

BIO 2022

June 13-16, 2022

Read More
catalym
Posted by catalym
January 26, 2022
January 26, 2022

ESMO 2022

September 9-13, 2022

Read More
catalym
Posted by catalym
January 26, 2022
January 26, 2022

SITC 2022

November 8-12, 2022

Read More
catalym
Posted by catalym
November 15, 2021
November 15, 2021

Tumor-derived GDF-15 prevents therapy success of checkpoint inhibitors by blocking T-lymphocyte recruitment

Markus Haake, Tina Schäfer, Beatrice Haack, Neha Vashist, Sabrina Genßler, Patrick Harter,...

Read More
catalym
Posted by catalym
November 15, 2021
November 15, 2021

A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced stage solid tumors (Acronym: GDFATHER)

Ignacio Melero, Emiliano Calvo, Maria-Elisabeth Goebeler, Elena Garralda, Reinhard Dummer, María Rodríguez-Ruiz,...

Read More
catalym
Posted by catalym
November 12, 2021
November 12, 2021

CatalYm Presents Expanded Clinical and New Preclinical Data from GDF-15-targeting Program CTL-002 at SITC Conference

CatalYm Presents Expanded Clinical and New Preclinical Data from GDF-15-targeting Program CTL-002...

Read More